0.5468
Precedente Chiudi:
$0.5411
Aprire:
$0.5429
Volume 24 ore:
478.83K
Relative Volume:
0.11
Capitalizzazione di mercato:
$14.51M
Reddito:
-
Utile/perdita netta:
$-26.56M
Rapporto P/E:
-0.8412
EPS:
-0.65
Flusso di cassa netto:
$-22.29M
1 W Prestazione:
-2.01%
1M Prestazione:
+26.78%
6M Prestazione:
-42.97%
1 anno Prestazione:
-59.68%
BiomX Inc Stock (PHGE) Company Profile
Nome
BiomX Inc
Settore
Industria
Telefono
972 7 23942377
Indirizzo
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
Confronta PHGE con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
PHGE
BiomX Inc
|
0.5468 | 13.66M | 0 | -26.56M | -22.29M | -0.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2021-04-15 | Iniziato | Ladenburg Thalmann | Buy |
BiomX Inc Borsa (PHGE) Ultime notizie
Published on: 2025-08-20 04:33:53 - classian.co.kr
BiomX announces U.S. FDA placed clinical hold on Phase 2b trial of BX004 - TipRanks
BiomX’s mid-stage cystic fibrosis trial put on clinical hold; Santen makes a deal with RemeGen - Endpoints News
Correction to BiomX Article - MarketScreener
BiomX Faces FDA Hold on Phase 2b Study - TipRanks
BiomX's BX004: A Phage Therapy Revolution in the Orphan Drug Market - AInvest
BiomX Inc. Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis - MarketScreener
BiomX Inc. Reports Q2 2025 Progress and Financials - MSN
Technical Models Suggest BiomX Inc. May Rebound SoonJuly 2025 Breakouts & High Accuracy Swing Entry Alerts - thegnnews.com
Does BiomX Inc. fit your quant trading modelQuarterly Profit Summary & Weekly Watchlist of Top Performers - Newser
Applying chart zones and confluence areas to BiomX Inc.Recession Risk & Scalable Portfolio Growth Ideas - Newser
What institutional flow reveals about BiomX Inc.July 2025 Fed Impact & Growth Focused Entry Point Reports - Newser
Should you wait for a breakout in BiomX Inc.2025 Market Sentiment & Stepwise Entry and Exit Trade Signals - Newser
Applying big data sentiment scoring on BiomX Inc.2025 Trading Recap & Verified Swing Trading Watchlists - Newser
Earnings visualization tools for BiomX Inc.2025 Bull vs Bear & Growth Focused Entry Point Reports - Newser
What Fibonacci levels say about BiomX Inc. reboundPortfolio Growth Summary & Long-Term Investment Growth Plans - Newser
BiomX Inc. Stock Performance After Earnings: Historical InsightsJuly 2025 Macro Moves & Free Technical Pattern Based Buy Signals - Newser
Can trapped investors hope for a rebound in BiomX Inc.July 2025 Sector Moves & Stock Portfolio Risk Management - Newser
BiomX Inc. stock prediction for this weekShare Buyback & Step-by-Step Trade Execution Guides - Newser
How BiomX Inc. stock performs during market volatilityTrade Analysis Summary & AI Enhanced Market Trend Forecasts - Newser
Analyzing drawdowns of BiomX Inc. with statistical toolsShort Setup & Accurate Technical Buy Alerts - Newser
BiomX Inc. (AMEX:PHGE) Q2 2025 Earnings Call Transcript - Insider Monkey
BiomX Inc. shares fall 2.82% premarket after reporting second quarter 2025 financial results. - AInvest
BiomX outlines BX004 Phase IIb results expected in Q1 2026 as BX211 advances toward registrational study - MSN
BiomX Posts Q2 Loss With 14% Cost Drop - AOL.com
BiomX's Q2 2025 Earnings Call: Unraveling Contradictions in BX211 and BX004 Development Strategies - AInvest
Trend analysis for BiomX Inc. this weekJuly 2025 Sector Moves & Short-Term High Return Ideas - Newser
BiomX Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Transcript : BiomX Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
BiomX Inc (PHGE) Reports Q2 2025 EPS of -$0.33, Net Loss of $6 M - GuruFocus
BiomX Reports Q2 GAAP EPS of -$0.19, Cash Balance Decreases to $15.2 Million - AInvest
BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates - TradingView
News impact scoring models applied to BiomX Inc.July 2025 News Drivers & Weekly Chart Analysis and Trade Guides - Newser
Technical Models Suggest BiomX Inc. May Rebound Soon [July 2025 Breakouts]Risk Managed Investment Entry Signals - 선데이타임즈
BiomX Announces Q2 2025 Financial Results and Initiates Phase 2B Trial for Cystic Fibrosis Treatment - AInvest
BiomX: Positioning Phage Therapy as a High-Probability, High-Impact Play in the Antibiotic Resistance Crisis - AInvest
How to escape a deep drawdown in BiomX Inc.Market Volume Summary & Reliable Momentum Entry Alerts - Newser
BiomX Earnings Preview: What to Expect on August 13th - AInvest
BiomX Inc.’s Price Action Aligns with Quant SignalsBreakout Confirmation With Entry Tracker Enabled - 선데이타임즈
What to Expect From BiomX's Earnings - 富途牛牛
Should I buy BiomX Inc. stock before earningsPredictive Analytics for Equity Growth Potential - Newser
Can BiomX Inc. hit a new high this monthIntraday Price Action Forecast Planner - Newser
Why BiomX Inc. is moving todayTrend Analysis for Safer Market Entries - Newser
BiomX (PHGE) Projected to Post Earnings on Wednesday - Defense World
BiomX Inc Azioni (PHGE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):